Botensilimab + Balstilimab for Colorectal Cancer

This trial aims to determine if combining two immunotherapy drugs, botensilimab and balstilimab, can treat certain types of colorectal cancer. The focus is on patients with stage II or III colorectal adenocarcinoma who have small amounts of cancer DNA in their blood, even after surgery and other treatments. These drugs may help the immune system fight remaining cancer cells and prevent their spread. This study might suit patients who have completed all planned treatments for colorectal cancer but still have detectable cancer DNA in their bloodstream. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group, offering a chance to benefit from potentially effective therapies.

The trial does not specify if you need to stop taking your current medications. However, you cannot be on any investigational drugs or immunosuppressive agents within 7 days before starting the trial treatment. It's best to discuss your specific medications with the trial team.

Previous studies have shown that the combination of botensilimab and balstilimab has a manageable safety profile in patients with colorectal cancer. Specifically, 89% of patients reported treatment-related side effects. The most common side effects included fatigue, affecting 35% of patients, and diarrhea, affecting 32%. Although common, these side effects were generally manageable. Additionally, the treatment demonstrated promising effectiveness, with many patients experiencing tumor shrinkage. Overall, research suggests that this combination is relatively well-tolerated in patients with advanced colorectal cancer.¹²³⁴⁵

Researchers are excited about the combination of balstilimab and botensilimab for colorectal cancer because these treatments target the immune system in a unique way. Unlike traditional chemotherapy, which directly kills cancer cells, balstilimab is an anti-PD-1 antibody that helps the immune system recognize and attack cancer cells. Botensilimab, on the other hand, is a novel immune-modulating antibody that enhances the immune response even further. This dual approach has the potential to improve treatment outcomes by effectively turning the body's own defenses against the cancer.

This trial will evaluate the combination of botensilimab and balstilimab for colorectal cancer. Studies have shown that using these two drugs together can be effective for patients with this condition. In one study, the treatment significantly reduced tumor size in 67.5% of patients with microsatellite stable (MSS) colorectal cancer. Another study found that about 23% of patients experienced a positive response, with tumor shrinkage. Additionally, this combination has proven safe, with no delays in surgery for patients receiving the treatment. These promising results suggest that botensilimab and balstilimab could be a strong option for treating colorectal cancer.⁶⁷⁸⁹¹⁰